The Future of Biotech Governance
In 2023, a research group based at Boston University and several other institutions published a paper describing a new SARS-CoV-2 variant they had constructed in the lab — combining the spike protein of Omicron with the genetic backbone of the original Wuhan strain.
In 2023, a research group based at Boston University and several other institutions published a paper describing a new SARS-CoV-2 variant they had constructed in the lab — combining the spike protein of Omicron with the genetic backbone of the original Wuhan strain. The chimeric virus killed 80% of the mice it infected, compared to roughly 0% mortality for naturally infected mice with Omicron alone.
The research was conducted in the United States, at institutions receiving federal funding, after the 2017 lifting of the gain-of-function pause. It used techniques and methods that had been discussed in the biosecurity community for years. The institutional biosafety committee at Boston University had approved it. The research was not classified or hidden — it was published in Nature.
When the work became public, it produced one of the largest biosecurity controversies in recent memory. Multiple federal agencies opened investigations. Congressional hearings followed. The institution's funding came under review. The basic policy questions — should this research have been allowed? was it adequately reviewed? who is responsible for deciding? — remained largely unanswered.
This isn't an isolated incident. It's the present condition of biotech governance: technically capable researchers conducting cutting-edge work under regulatory frameworks that don't really know how to evaluate it, in a globalized system where any country's permissiveness is effectively every country's risk. This module is the synthesis — and the question of what comes next.
---
The Pacing Problem
Every previous module in this track has touched on the same underlying issue. Technology accelerates. Law lags. The gap between them grows.
This phenomenon has a name in the policy literature: the pacing problem.
In biomedical contexts, the pacing problem manifests through several specific patterns:
Statutory time scales vs. technology time scales. Major US biotech statutes take decades to write and pass. The FD&C Act was 1938. GINA was 2008. Each was the result of years of legislative effort. Meanwhile, CRISPR went from initial discovery (2012) to first FDA-approved therapy (2023) in eleven years. The legislative response to gene editing is still in its early stages.
Regulatory capacity vs. technological complexity. Modern biotech requires specialized expertise to regulate competently. The FDA has built that expertise over decades — and still struggles with the most complex products. Newer biotech (synthetic biology, AI-designed therapeutics, novel modalities) outpaces regulatory training and hiring.
Geographic mobility vs. national jurisdiction. Research and development can move. If one country imposes burdensome regulation, research can shift to another. This pressure pushes nations toward permissive regulation to retain the industry. The result is a race that nobody wants to lose — but where losing might mean losing the industry, and winning might mean losing public safety guardrails.
Knowledge diffusion vs. regulatory containment. Once techniques are published, they diffuse rapidly. The CRISPR community grew from a few labs in 2012 to thousands of labs worldwide by 2017. Regulatory frameworks designed for "contain the technology to authorized actors" don't work when the technology is in every molecular biology textbook within years of its invention.
These aren't problems any single regulatory reform solves. They're structural features of contemporary biotech. The realistic question isn't "how do we close the pacing gap" — it's "how do we govern effectively despite it."
---
Specific Gap Areas
Where current US biotech governance is most clearly inadequate, in approximate order of immediacy:
Gene drives. Engineered genetic elements designed to spread through wild populations faster than normal inheritance. Could potentially eliminate disease-vector species (mosquitoes carrying malaria, invasive species), but releases are essentially permanent at ecosystem scale. Current US oversight runs through whatever agency has jurisdiction over the species in question (USDA, EPA, FDA depending on context). No comprehensive federal framework exists. Field releases have not happened in the US but are imminent in several other countries.
Xenotransplantation. Transplanting organs or tissue from non-human animals into humans. The first pig-to-human heart transplant happened in 2022. CRISPR-engineered pigs are now in clinical trials. The infectious disease implications (potential transmission of porcine viruses to humans) require novel public health oversight that the existing framework doesn't fully provide.
Embryo editing and reproductive technologies. As discussed in BP3 and BP7, the US legal framework for embryo research, IVF technologies, and reproductive genetic interventions is fragmented and incomplete. The He Jiankui case exposed the global gap; the US gap is also substantial.
Brain-computer interfaces and neurotech. Implantable devices that read or modulate neural activity. Neuralink and other companies have advanced rapidly. The FDA has device authority, but specific frameworks for neuro-data privacy, long-term effects, and equity of access barely exist.
AI-enabled biotech. Machine learning models that design proteins, predict structures, suggest drug candidates, or assist in synthetic biology. Most operate outside any specific biotech regulatory framework. Both safety risks (AI-assisted bioweapon development) and integration with existing approval pathways are inadequately addressed.
Synthetic biology at scale. Engineered microbes for industrial production, environmental cleanup, agriculture, or other deployments. Existing frameworks (EPA's TSCA, USDA's plant pest authority) were designed for narrower questions and don't adequately address ambitious environmental synthetic biology.
Mirror life. Organisms built from mirror-image biological molecules. Genuinely hypothetical for now, but technically plausible within decades. Would have unprecedented biological properties — immune to natural decomposition, potentially capable of catastrophic ecological displacement. Essentially zero current regulatory framework exists.
Mass personalized medicine. As gene therapies and other treatments become individualized, the standard clinical trial framework breaks down (you can't run a randomized controlled trial with n=1). New evidentiary and approval frameworks are needed but not yet developed.
This is not an exhaustive list. It's a sample. Each of these areas could be a research project in itself. Each represents a gap in current US biotech governance.
---
International Comparisons
US biotech policy doesn't exist in isolation. Comparison with other major biotech jurisdictions sharpens what's distinctive about US approaches and what reform options might exist.
The European Union operates the most precautionary biotech regulatory framework globally. The EU's GMO regulations explicitly use the precautionary principle — restricting action until safety is established, rather than allowing action until harm is shown. The EU regulates gene editing more strictly than the US (BP4), has stronger genetic privacy protections (the GDPR extends to genetic data with explicit provisions), and has more centralized regulatory authority (the European Medicines Agency operating like a continental FDA equivalent).
EU advantages: Strong public confidence in food and drug safety. Robust consumer protections. Coordinated approach across member states.
EU disadvantages: Slower drug approvals. Less domestic biotech innovation in some sectors. Higher costs.
The United Kingdom is in an interesting position post-Brexit. The UK is establishing somewhat distinct biotech regulation from the EU — generally more permissive, especially on gene-edited agriculture. The Human Fertilisation and Embryology Authority (HFEA) is the UK's specialized regulator for reproductive technologies — a body the US doesn't have an equivalent of. The HFEA has approved specific embryo editing research, mitochondrial replacement therapy, and other interventions that have no clear US regulatory pathway.
UK advantages: Specialized regulatory bodies for emerging areas. Selective post-Brexit modernization opportunities. Strong scientific community.
UK disadvantages: Smaller scale than EU or US. Regulatory uncertainty during Brexit transition. Limited international leverage compared to larger jurisdictions.
China has expanded its biotech regulatory framework dramatically since the He Jiankui case. The 2019 amendments to the Regulations on Ethical Review of Biomedical Research strengthened oversight. New laws on biosecurity (2021) and human genetic resources (2023) tightened control over genetic data, research approvals, and international collaboration. China's approach combines aggressive biotech development support with increasingly strict regulation — a model that's neither US-style permissive nor EU-style precautionary.
China advantages: Massive R&D investment. Centralized regulatory decision-making (when working). Specific frameworks for emerging areas.
China disadvantages: Transparency limitations. International confidence issues. Tension between political control and scientific independence.
Japan, South Korea, Singapore, and other Asia-Pacific countries have developed sophisticated biotech regulatory frameworks tailored to local priorities. Japan's regulatory approach to regenerative medicine has been notably more permissive than the US's, allowing conditional approval based on safety data alone with confirmation of efficacy required post-market. Singapore has built itself as a biotech hub with selective regulatory features.
Brazil, India, and other Global South countries have varied approaches, often combining specific national priorities (agricultural biotechnology for food security in many cases) with constrained regulatory capacity. The capacity issue is often more pressing than the legal framework — laws may exist but enforcement is variable.
Comparative lessons:
The US is on the more permissive end of biotech regulation globally — especially for agricultural biotech and DTC genetics. The US has the most developed framework for medical biotech (FDA gene therapy approvals are world-leading) but the weakest framework for environmental and ecological biotech compared to EU. US privacy protection is generally weaker than EU's GDPR-based framework. US has stronger biosecurity statutes than most countries but uneven implementation.
There's no single "best" model. Each framework reflects different value tradeoffs. Understanding the alternatives is essential to imagining what US reforms could look like.
---
Reform Directions and the Path Forward
What's the realistic policy agenda for modernizing US biotech governance?
Modernizing the Coordinated Framework. The 1986 framework is older than most current biotech researchers. Replacing it is politically challenging — the existing structure has stakeholders who benefit from it — but updates are possible. The 2022 OSTP Bioeconomy Executive Order directed agencies to begin this work; results have been incremental. A more ambitious modernization would address the specific gaps in this module.
Strengthening genetic privacy. Closing GINA's gaps to cover life, disability, and long-term care insurance is a frequently-introduced bipartisan idea. Extending HIPAA-equivalent protections to DTC genetic testing companies is another. Federal preemption of state genetic privacy laws (toward stronger protection) would resolve the patchwork.
Building emerging technology frameworks. Specific regulatory frameworks for gene drives, neurotech, xenotransplantation, and AI-enabled biotech could fill major gaps. Some of this work is happening — FDA has new guidance documents on cell and gene therapy; the 2024 DURC update addressed some biosecurity gaps. More is needed.
Equity in biotech access. Drug pricing reform, especially for gene therapies, is one of the major unresolved issues. The Inflation Reduction Act of 2022 introduced limited Medicare drug price negotiation; how this applies to gene therapies is still being worked out. More fundamental access reforms — pricing controls, public manufacturing, value-based insurance design — remain politically contested.
International coordination. The fragmented international biotech governance landscape creates regulatory arbitrage and undermines containment of high-risk research. The WHO has limited authority. New international bodies are politically difficult to create. Bilateral and multilateral agreements on specific issues (DURC, germline editing) are more realistic but slow to develop.
State-level innovation. States are often laboratories for biotech policy innovation. California has been particularly active in genetic privacy and stem cell research. Other states could lead on similar issues. State experimentation, when successful, can demonstrate models for federal adoption.
Capacity-building. Strengthening the institutional capacity of FDA, NIH, state public health departments, and other regulatory bodies is a precondition for effective governance regardless of legal reforms. This is unglamorous, requires sustained budget commitment, and is politically vulnerable — but it underlies everything else.
The honest summary: comprehensive biotech governance reform isn't on the immediate political horizon. Incremental improvements are happening. The biggest gaps will likely persist for the foreseeable future. Effective policy work in this space is partly about closing specific gaps and partly about being ready when larger reform windows open.
This is the policy field. It's slow, contested, partial, and consequential. The technology will continue to advance regardless. Whether governance catches up depends substantially on people doing the work.
---
Wait, Actually...
There's a possibility that biotech governance reform happens not through the slow legislative process but through a major incident.
The pattern is historically consistent. Modern FDA authority emerged from Elixir Sulfanilamide (1937). Modern gene therapy oversight emerged from Jesse Gelsinger's death (1999). Modern biosecurity policy strengthened after the 2001 anthrax attacks and again after COVID-19. Major regulatory frameworks have repeatedly been built in response to specific tragedies, not through proactive reform.
This is a deeply unsatisfying pattern. It means that the most likely path to better biotech governance involves something terrible happening first. It also means that pre-existing reform agendas — the kind of work this module references — become enormously consequential after a triggering event. Policy frameworks developed in advance, even if not adopted in the moment, can shape what gets enacted when crisis forces action.
This is one of the reasons careful policy work matters even when the immediate political environment doesn't reward it. The frameworks built today are the frameworks deployed tomorrow when reform becomes politically possible.
This is also why academic work like Hodge's, advocacy by public health organizations, and serious policy analysis of biotech gaps — work that doesn't produce immediate legislative results — is important even when it appears to fail. The reform options that matter are the ones that have been carefully worked out before they're needed.
You are now positioned to do that kind of work. That's the entire point of this track.
---
What is "the pacing problem" in biotech policy?
Which country's regulatory model uses the strongest version of the "precautionary principle" for biotech?
What is the UK's HFEA, and why is it significant in biotech policy?
Which historical pattern has often driven major biotech regulatory reform?
Capstone Mini-Project: Synthesize Your Track
This is the final BP module. Your capstone for the Biotech Policy track is a synthesis piece.
Pick one of these:
Option A: White Paper Format
Write a 2,000–3,000 word policy white paper proposing a specific reform to US biotech governance. The paper should:
- Identify a specific gap or problem in current law/regulation
- Provide background context, with cited references from this track and from outside reading
- Survey how other jurisdictions handle the same issue
- Propose a specific reform — statutory change, regulatory update, agency reorganization, or similar
- Address anticipated counterarguments and political feasibility
- Conclude with concrete next steps
This is the format used by academic policy scholars, think tanks, and congressional staff. It's also exactly what your independent research with Hodge could plausibly produce as a final output.
Option B: Comparative Analysis
Write a 2,000–3,000 word comparative analysis of how a specific biotech challenge (gene editing, genetic privacy, gain-of-function research, or another) is handled in 3–4 different jurisdictions. The analysis should:
- Describe the technology and the policy challenge it poses
- Examine the regulatory approach in each jurisdiction with specifics
- Identify the strengths and weaknesses of each approach
- Draw broader lessons about biotech governance
- Conclude with implications for US policy
Option C: Advocacy Document
Draft a complete advocacy package for a specific biotech policy reform. Include:
- A one-page executive summary
- A more detailed 1,500-word brief
- A draft op-ed for general public audience
- A talking points document for legislative staff
- A list of likely allies and opponents
This is what real advocacy organizations produce. The format is unfamiliar but essential to learn if you're going to do policy work at any level.
Whichever option you choose, this capstone is meant to be portable. The work should be usable — as a writing sample for applications, as a draft you could discuss with Hodge, as a starting point for further research. Take it seriously.
---
You Finished the Biotech Policy Track
If you completed all eight modules in this track with serious engagement, you have a working understanding of US biotech regulation that exceeds what most people who work professionally in adjacent fields actually possess. Most clinicians don't know how FDA approval works. Most biotech professionals don't know what state public health authority means. Most policy generalists don't know the difference between somatic and germline editing. You now know all of these things.
The track is also a foundation for your specific research interests — the independent research with Hodge on public health law gaps, the broader question of how biotech governance can keep pace with biotech innovation, the specific cases (CRISPR, gene drives, AI-enabled biotech) that will define this policy space for the next decade.
What you do with this is up to you.
The ocean was Marine Biology's frontier. Genetic engineering and emerging biotech are this track's. You're now equipped to work at that frontier. Not from the periphery — from the center, where the conversations actually happen.
---